The MFDS handles post-marketing surveillance in South Korea by monitoring the safety and efficacy of approved drugs through adverse event reporting systems. It collects data from healthcare providers and patients, analyzes trends, and conducts periodic reviews. The MFDS can issue safety warnings, require additional studies, or withdraw products if significant risks are identified.
